Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.7K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules.

Journal of medicinal chemistry·2026
Same author

Ugi-Tetrazole-Derived α‑Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV‑2 3CLpro.

ACS medicinal chemistry letters·2026
Same author

Systematic Expansion of an Ugi-Based Multicomponent Synthesis of Tetrasubstituted Imidazoles.

ACS omega·2026
Same author

Precipitation-first synthesis and deep profiling of a 1200-member acrylamide library for covalent drug discovery.

Green chemistry : an international journal and green chemistry resource : GC·2025
Same author

Colchicine-BODIPY Probes: Evidence for the Involvement of Intracellular Membranes in the Targeting of Colchicine to Tubulin.

ACS pharmacology & translational science·2025
Same author

Balinatunfib: A Clinical Oral Small Molecule TNFα Inhibitor.

ChemMedChem·2025

Related Experiment Video

Updated: Apr 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Baxdrostat: A First-in-Class Aldosterone Synthase Inhibitor for Resistant Hypertension.

Imma Capriello1,2, Alexander Dömling1,2

  • 1Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Slechtitelů 27, 77900 Olomouc, Czech Republic.

ACS Pharmacology & Translational Science
|April 16, 2026
PubMed
Summary
This summary is machine-generated.

Baxdrostat, a new aldosterone synthase inhibitor, effectively lowers blood pressure in patients with resistant hypertension. This breakthrough offers a promising new treatment for managing this challenging cardiovascular condition.

Keywords:
BaxdrostatCYP11B2aldosterone synthasecardiovascular pharmacologyresistant hypertensionstructure-based drug design

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.6K

Related Experiment Videos

Last Updated: Apr 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.6K

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Resistant hypertension affects millions globally, increasing risks of stroke, heart failure, and kidney disease.
  • Aldosterone excess is a key factor in treatment-resistant hypertension.
  • Selective inhibition of aldosterone synthase (CYP11B2) has been challenging due to its similarity to CYP11B1.

Purpose of the Study:

  • To review the role of aldosterone in hypertension.
  • To discuss the development and clinical evaluation of Baxdrostat, a selective aldosterone synthase inhibitor.
  • To explore the implications of targeting steroidogenic cytochrome P450 enzymes.

Main Methods:

  • Review of existing literature on aldosterone pathophysiology and CYP11B2 inhibition.
  • Summary of the discovery and preclinical development of Baxdrostat.
  • Analysis of Phase 3 clinical trial data for Baxdrostat in resistant hypertension.

Main Results:

  • Baxdrostat demonstrated significant blood pressure reduction in Phase 3 trials.
  • The drug is an orally bioavailable, highly selective aldosterone synthase inhibitor.
  • This marks a potential paradigm shift in resistant hypertension management.

Conclusions:

  • Baxdrostat represents a significant advancement in treating resistant hypertension.
  • Targeting CYP11B2 offers a novel therapeutic strategy.
  • Further research will explore Baxdrostat's role in cardiovascular pharmacopeia.